Organisation paid for research Program year 2024 Source: CMS Open Payments

Beaver Medical Group

Neither a doctor nor a teaching hospital

Research payments

$34,082

48 payments

Through program year 2024, Beaver Medical Group is reported as receiving $34,082 in research payments, across 48 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$4,932	3
2023	Research	$4,522	3
2021	Research	$11,003	20
2019	Research	$13,625	22

Breakdown

Who paid Research payments · program years 2019–2024

Incyte Corporation $34,082 48 payments

Studies the money was for Research payments · program years 2019–2024

Prospective, Longitudinal, Non Interventional Study of Disease Burden and Treatment of Patients With Low Risk Myelofibrosis MF Or High Risk Essential Thrombocythemia Et Or Et Patients Receiving Et Directed Therapy $10,855 12 payments
Prospective, Longitudinal, Non Interventional Study of Disease Burden and Treatment of Patients With Low Risk Myelofibrosis (MF) Or High Risk Essential Thrombocythemia (Et) Or Et Patients Receiving Et Directed Therapy $8,154 5 payments
Prospective, Non Interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic Or Community Clinical Practices $7,820 2 payments
Prospective, Longitudinal, Non Interventional Study of Disease Burden and Treatment of Patients With Low Risk Myelofibrosis (MF) Or High Risk Essential Thrombocythemia (Et) Or Et Patients Receiving Et Directed Therapy $3,207 19 payments
A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea RESET 272 $2,746 9 payments
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib $1,300 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.